Abstract
Recent developments regarding the Internet of Things (IoT), Artificial Intelligence (AI), and Machine Learning (ML) opened new horizons of healthcare opportunities. Moreover, these technological advancements give strength to face upcoming healthcare challenges. One of such challenges is the advent of COVID-19, which has adverse effects beyond comprehension. Therefore, utilizing the basic functionalities of IoT, this work presents a real-time rule-based Fuzzy Logic classifier for COVID-19 Detection (FLCD). The proposed model deploys the IoT framework to collect real-time symptoms data from users to detect symptomatic and asymptomatic Covid-19 patients. Moreover, the proposed framework is also capable of monitoring the treatment response of infected people. FLCD constitutes three components: symptom data collection using wearable sensors, data fusion through Rule-Based Fuzzy Logic classifier, and cloud infrastructure to store data with a possible verdict (normal, mild, serious, or critical). After extracting the relevant features, experiments with a synthetic COVID-19 symptom dataset are conducted to ensure effective and accurate detection of COVID-19 cases. As a result, FLCD successfully acquired 95% accuracy, 94.73% precision, 93.35% recall, and showed a minimum error rate of 2.52%.
Highlights
In December 2019, a novel coronavirus SARS-CoV-2 was exposed to the world, later named COVID-19. It is a newly identified infectious disease belonging to the coronavirus family, spreads through person-to-person contact [1]
Researchers from the medicine domain worldwide worked incessantly and produced a handful of vaccines, which are approved by National regulatory authorities and WHO for emergency use [3]
WHO has approved seven vaccines for emergency use; mRNA by Moderna, BioNTech by Pfizer, Janssen by Johnson and Johnson, AstraZeneca by the University of Oxford, Covishield by Serum Institute of India, Sinopharm by Beijing Institute of Biological Products, and Sinovac-CoronaVac by Sinovac, giving the green light for these vaccines to be rolled out globally as they have the potential to reduce the possibility of getting infected by COVID-19 virus [4]
Summary
In December 2019, a novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome) was exposed to the world, later named COVID-19. It is a newly identified infectious disease belonging to the coronavirus family, spreads through person-to-person contact [1]. WHO has approved seven vaccines for emergency use; mRNA by Moderna, BioNTech by Pfizer, Janssen by Johnson and Johnson, AstraZeneca by the University of Oxford, Covishield by Serum Institute of India, Sinopharm by Beijing Institute of Biological Products, and Sinovac-CoronaVac by Sinovac, giving the green light for these vaccines to be rolled out globally as they have the potential to reduce the possibility of getting infected by COVID-19 virus [4]. Only 1.4% population of low-income countries have received at least
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
